Shanghai RAAS clears antitrust hurdle for Nanyue acquisition

Shanghai RAAS Blood Products (SZSE:002252) announced it has cleared all required overseas antitrust reviews related to its acquisition of Nanyue Biopharmaceutical Co., Ltd. The acquisition involves the purchase of 87.9766% equity in Nanyue Biopharmaceutical from individual shareholders including Liu Lingan, Changsha Dexin Biological Technology Partnership, Chen Yu, Xiao Hanzu, and Wang Xiangying. Additionally, the company will acquire 12.0234% equity held by Hunan Xingxiang Funds. With antitrust hurdles cleared, Shanghai RAAS Blood Products is progressing with the deal, with official closing pending, with the company monitoring developments and plans to disclose further information as required.